Available Forms: injection (prefilled syringe)
Available Strengths: 120mg
Reference Brands: ENSPRYNG (USA/EU)
Category: Neurology
Satralizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) pathway to reduce inflammatory activity in neuromyelitis optica spectrum disorder (NMOSD). It is indicated (as monotherapy or with immunosuppressants) for AQP4-antibody positive adults with NMOSD and is given by subcutaneous injection (loading doses at Weeks 0, 2, 4, then every 4 weeks maintenance). The approved commercial name in the US, EU and UK is ENSPRYNG and the licensed presentation is a single-use 120 mg/1 mL prefilled syringe. Common important safety notes include an increased risk of serious infections; screening for infections (including hepatitis B / TB) and vaccination status should be reviewed before starting therapy.
Quick Response Guaranteed | Verified Suppliers
Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that affects the optic nerves and spinal cord. It helps reduce inflammation and prevent relapses by blocking the interleukin-6 (IL-6) receptor, which plays a key role in the immune system’s inflammatory response.
Satralizumab is made from Satralizumab-mwge, a humanized monoclonal antibody that specifically targets the IL-6 receptor to control immune system overactivity.
The trade name of Satralizumab is Enspryng.
Satralizumab (Enspryng) is developed and manufactured by Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and marketed by Genentech in various countries.
The generic name of Satralizumab is Satralizumab-mwge.
The brand name of Satralizumab is Enspryng.
Satralizumab is manufactured in Japan and Switzerland by Chugai Pharmaceutical and Roche, and distributed globally under regulatory approvals for NMOSD treatment.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP